← Leaderboards
Kathryn Ann Morton
Oregon Health And Science University
$27,424,848
Attributed
$29,929,297
Total exposure
7
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $795.2K · FY2006–19$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$29,929,297 · 7
By mechanism
U09$22,443,000 · 1
R01$6,149,175 · 3
R21$1,015,819 · 2
P50$321,303 · 1
Top collaborators
- John M Hoffman7 shared
- Rheal A Towner5 shared
- Jeffrey T Yap5 shared
Most similar at Oregon Health And Science University
Same institution · by research overlap
- Svetlana Lutsenko$18,670,781
Research focus
Positron-Emission TomographyBaseFluorodeoxyglucose Positron Emission TomographyLinkAcuteImageUptakeMetabolicResponseMolecular ImagingInflammationInflammatoryGenesImaging DeviceRattusFutureCytokineEventBrainMalignant NeoplasmsGalliumBiological TransportGas Chromatography Mass SpectrometryBlood - Brain Barrier Anatomy
Grant awards (28)
Causes, consequences, imaging and mitigation of sepsis-induced encephalopathy$581,379
R01 · FY2019 · NS · contact PI
Causes, consequences, imaging and mitigation of sepsis-induced encephalopathy$593,428
R01 · FY2018 · NS · contact PI
Causes, consequences, imaging and mitigation of sepsis-induced encephalopathy$593,428
R01 · FY2017 · NS · contact PI
Causes, consequences, imaging and mitigation of sepsis-induced encephalopathy$576,124
R01 · FY2016 · NS · contact PI
Causes, consequences, imaging and mitigation of sepsis-induced encephalopathy$588,164
R01 · FY2015 · NS · contact PI
MULTI-TRACER PET ASSESSMENT OF RESPONSE TO NOVEL TARGETED CHEMOTHERAPY$299,900
R21 · FY2014 · CA
MULTI-TRACER PET ASSESSMENT OF RESPONSE TO NOVEL TARGETED CHEMOTHERAPY$310,213
R21 · FY2012 · CA
FDG PET in cancer-associated venothromboembolic disease$450,503
R01 · FY2009 · CA · contact PI
FDG PET in cancer-associated venothromboembolic disease$450,503
R01 · FY2008 · CA · contact PI
CORE--IMAGING$166,970
P50 · FY2008 · DA · contact PI
FDG PET in cancer-associated venothromboembolic disease$459,424
R01 · FY2007 · CA · contact PI
Imaging phenotypes in copper metabolism disease in mice$181,456
R21 · FY2007 · EB · contact PI
CORE--IMAGING$154,333
P50 · FY2007 · DA · contact PI
FDG PET in cancer-associated venothromboembolic disease$530,266
R01 · FY2006 · CA · contact PI
Imaging phenotypes in copper metabolism disease in mice$224,250
R21 · FY2006 · EB · contact PI
Tumor uptake of Ga-67 by photodegraded nifedipine$279,191
R01 · FY2004 · CA
Tumor uptake of Ga-67 by photodegraded nifedipine$253,457
R01 · FY2003 · CA
TECHNICAL AND APPLIED SCIENCES$6,817,000
U09 · FY2002 · RG
TECHNICAL AND APPLIED SCIENCES$3,958,000
U09 · FY2002 · RG
Tumor uptake of Ga-67 by photodegraded nifedipine$264,520
R01 · FY2002 · CA
TECHNICAL AND APPLIED SCIENCES$2,875,000
U09 · FY2001 · RG
TECHNICAL AND APPLIED SCIENCES$2,610,000
U09 · FY2001 · RG
TECHNICAL AND APPLIED SCIENCES$2,576,000
U09 · FY2001 · RG
TECHNICAL AND APPLIED SCIENCES$900,000
U09 · FY2001 · RG
TUMOR UPTAKE OF GA67 BY PHOTODEGRADED NIFEDIPINE$259,570
R01 · FY2001 · CA
TUMOR UPTAKE OF GA67 BY PHOTODEGRADED NIFEDIPINE$8,082
R01 · FY2001 · CA
TECHNICAL AND APPLIED SCIENCES$2,707,000
U09 · FY2000 · RG
TUMOR UPTAKE OF GA67 BY PHOTODEGRADED NIFEDIPINE$261,136
R01 · FY2000 · CA